There are also early studies on combination 225Ac-PSMA and 177Lu-PSMA-617 therapy, which suggest that the combination may enhance responses to PSMA-targeted radiotherapy while limiting xerostomia [114]. This evidence concerns the gene FOLH1 and xerostomia.